Contact: Garth Sundem
University of Colorado Denver
Caption: University of Colorado Cancer Center investigator Tracey Schefter, M.D., and colleagues report promising results for the addition of bevacizumab (Avastin) to standard of care in locally advanced cervical cancer.
Credit: UC Denver
Usage Restrictions: None
Related news release: Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'